Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PT at $53.40

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $53.40.

Several research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Needham & Company LLC reiterated a “buy” rating and set a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Truist Financial set a $58.00 price objective on shares of Collegium Pharmaceutical in a research note on Tuesday, February 10th. Finally, Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th.

Insider Activity at Collegium Pharmaceutical

In related news, EVP David Dieter sold 13,976 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the transaction, the executive vice president owned 77,071 shares in the company, valued at $2,691,319.32. The trade was a 15.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Scott Dreyer sold 49,976 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total value of $2,019,530.16. Following the sale, the executive vice president owned 71,770 shares in the company, valued at $2,900,225.70. The trade was a 41.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 1.85% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of large investors have recently modified their holdings of COLL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Collegium Pharmaceutical by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock worth $569,000 after acquiring an additional 825 shares during the last quarter. Millennium Management LLC grew its stake in shares of Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after acquiring an additional 461,914 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Collegium Pharmaceutical by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after acquiring an additional 4,625 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Collegium Pharmaceutical by 218.7% during the first quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock worth $3,926,000 after acquiring an additional 90,255 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Collegium Pharmaceutical by 3.7% during the second quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock worth $2,131,000 after acquiring an additional 2,592 shares during the last quarter.

Collegium Pharmaceutical Stock Performance

COLL stock opened at $32.28 on Tuesday. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of 18.88 and a beta of 0.77. The firm has a 50-day simple moving average of $37.07 and a two-hundred day simple moving average of $41.41. Collegium Pharmaceutical has a one year low of $25.98 and a one year high of $50.79. The company has a debt-to-equity ratio of 2.59, a quick ratio of 1.48 and a current ratio of 1.57.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing the consensus estimate of $2.20 by ($0.16). The firm had revenue of $205.45 million for the quarter, compared to analysts’ expectations of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The business’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.77 earnings per share. On average, equities analysts forecast that Collegium Pharmaceutical will post 6.51 EPS for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.